Sarepta Therapeutics,, Inc. - SRPT STOCK NEWS

Sarepta Therapeutics (NASDAQ:SRPT) has announced a leadership transition, appointing Louise Rodino-Klapac, Ph.D., as head of research and development (R&D) effective immediately. She continues her role as chief scientific officer, following the departure of Gilmore O’Neill, who will serve as a consultant through March 31, 2022. Dr. Rodino-Klapac has been instrumental in the advancement of Sarepta’s gene therapy platform. Under O’Neill’s leadership, the R&D team achieved significant milestones, including the approval of RNA-based therapies for Duchenne muscular dystrophy and the initiation of pivotal trials.

Sarepta Therapeutics (NASDAQ:SRPT) has appointed Dr. Stephen L. Mayo, a distinguished protein engineering expert, to its Board of Directors effective immediately. Dr. Mayo, who currently holds a professorship at Caltech and serves on Merck's board, brings extensive scientific knowledge and business insights. The leadership highlights that Dr. Mayo's expertise will enhance Sarepta's capabilities as it advances its gene therapy pipeline. This strategic addition aims to bolster the company's position in genetic medicine for rare diseases.

Sarepta Therapeutics (SRPT) reported a 37% increase in net product sales for Q3 2021, totaling $166.9 million. Due to strong performance, the company raised its full-year guidance by $40 million, now projecting revenues of $605-$615 million. This marks the 20th consecutive quarter of revenue growth. Sarepta launched two pivotal trials for its therapies targeting Duchenne muscular dystrophy and presented promising data for its gene therapy programs. The company ended Q3 with over $2 billion in cash and equivalents, positioning it for future development.

Sarepta Therapeutics (NASDAQ:SRPT) announced participation in three virtual investor conferences. Senior management will engage in fireside chats at:

• Credit Suisse 30th Annual Healthcare Conference on November 9, 2021 at 12:10 p.m. E.T.
• Barclays Gene Editing & Gene Therapy Summit on November 15, 2021 at 3:00 p.m. E.T.
• Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021 at 1:25 p.m. E.T.

Webcasts will be available on Sarepta’s website, archived for 90 days. The company focuses on precision genetic medicine for rare diseases.

Sarepta Therapeutics (NASDAQ:SRPT) announced on October 29, 2021, equity awards for 17 newly hired employees as part of its 2014 Employment Commencement Incentive Plan. The total awards include options to purchase 15,025 shares and 7,975 restricted stock units (RSUs). The exercise price of the options is set at $79.13 per share, aligned with the stock's closing price on the grant date. Options will vest over four years, while RSUs will vest annually over the same period, contingent on continued employment.

Sarepta Therapeutics (NASDAQ:SRPT) is set to report its third quarter 2021 financial results on November 3, 2021, after the market closes. A conference call will follow at 4:30 p.m. E.T. to discuss financial results and provide corporate updates. Investors can access the call by dialing (844) 534-7313 for domestic calls or (574) 990-1451 internationally, using passcode 7131019. The call will also be available via live webcast on the company's investor relations website and archived for 90 days.

Sarepta Therapeutics (NASDAQ:SRPT) has announced a public offering of 6,172,840 shares at $81.00 per share, aiming for gross proceeds of approximately $500 million. Underwriters have a 30-day option to acquire an additional 925,926 shares. Proceeds will primarily fund clinical trials, commercialization, and business development activities. The offering is expected to close around October 18, 2021, pending customary conditions. Notably, the shares are offered under an effective shelf registration statement filed with the SEC.

Sarepta Therapeutics (NASDAQ:SRPT) reported preliminary Q3 2021 financial results, projecting net product revenues of approximately $166.9 million, a significant increase from $121.4 million in Q3 2020. As of September 30, 2021, the company reported $1.6 billion in cash and investments, down from $1.9 billion at the end of 2020. The results are preliminary, and actual results may vary as they have not yet been finalized or reviewed by independent auditors.

Sarepta Therapeutics (Nasdaq: SRPT) announced a public offering of $500 million in common stock, with an additional $75 million option for underwriters. The proceeds will finance clinical trials, commercialization, and business development, including potential acquisitions. Goldman Sachs, J.P. Morgan, Morgan Stanley, and Credit Suisse are the underwriters. The offering is conducted under an effective shelf registration statement filed with the SEC. A preliminary prospectus will detail the terms.